|
Nilotinib (AMN107, trade name Tasigna〔Official Manufacturer Website http://www.tasigna.com〕), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance.〔Jabbour, E., Cortes, J., Kantarjian, H. (2009). "Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review". ''Core evidence'' 4: 207-213.〕 Nilotinib is a selective Bcr-Abl kinase inhibitor〔〔 that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.〔〔〔 ==Medical uses== It is FDA- (29 October 2007),〔(【引用サイトリンク】work=Drugs.com )〕 EMA- (29 September 2009), MHRA- (19 November 2007) and TGA- (17 January 2008) approved for use as a treatment for Philadelphia Chromosome (Ph+)-positive Chronic myelogenous leukaemia. In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib, another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to imatinib) achieved normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications. The use of low doses of nilotinib is being investigated for use for Parkinson's, and Alzheimer's disease, as well as for ALS, dementia and Huntington's disease.〔http://medicalxpress.com/news/2013-05-cancer-drug-build-up-toxic-brain.html〕 Novartis announced on April 11, 2011 that it is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumor (GIST) based on the recommendation of an independent data monitoring committee. Interim results showed Tasigna is unlikely to demonstrate superiority compared to Novartis's Glivec® (imatinib) *, the current standard of care in this setting.〔http://www.novartis.com/newsroom/media-releases/en/2011/1504991.shtml〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nilotinib」の詳細全文を読む スポンサード リンク
|